We are live on ! Find out more
IHE icon

iShares US Pharmaceuticals ETF

82 hedge funds and large institutions have $147M invested in iShares US Pharmaceuticals ETF in 2019 Q3 according to their latest regulatory filings, with 9 funds opening new positions, 17 increasing their positions, 34 reducing their positions, and 13 closing their positions.

New
Increased
Maintained
Reduced
Closed

212% more capital inflows, than outflows

Capital inflows: $66.4M | Capital outflows: $21.3M

12.54% more ownership

Funds ownership: 34.17% → 46.71% (+13%)

6% less funds holding

Funds holding: 87 → 82 (-5)

31% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 13

50% less repeat investments, than reductions

Existing positions increased: 17 | Existing positions reduced: 34

100% less call options, than puts

Call options by funds: $1K | Put options by funds: $348K

Holders
82
Holders Change
-5
Holders Change %
-5.75%
% of All Funds
1.79%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
9
Increased
17
Reduced
34
Closed
13
Calls
$1​K
Puts
$348​K
Net Calls
-⁠$347​K
Net Calls Change
-⁠$349​K

IHE Hedge Fund Activity: Q3 2019 in Review

82 of the 4,577 institutional investors tracked by Wall St. Rank reported a position in iShares US Pharmaceuticals ETF (IHE) for Q3 2019, worth a combined $147M — up 33% from $111M a quarter earlier.

Sellers outnumbered buyers: 13 funds closed out of IHE and 9 opened new positions — a net loss of 4 holders — while 34 trimmed existing stakes and 17 added.

The largest buyer was Goldman Sachs, adding an estimated $57.5M. The largest seller was Jane Street, cutting an estimated $6.2M.

  • 82 institutional investors held iShares US Pharmaceuticals ETF (IHE) as of Q3 2019, down from 87 in Q2 2019.
  • Funds reported $147M of iShares US Pharmaceuticals ETF stock for Q3 2019, up 33% quarter-over-quarter.
  • 9 funds opened new iShares US Pharmaceuticals ETF positions in Q3 2019 and 13 closed out, a net change of -4 holders.
  • The largest iShares US Pharmaceuticals ETF buyer in Q3 2019 was Goldman Sachs, an estimated $57.5M added.
  • The largest iShares US Pharmaceuticals ETF seller in Q3 2019 was Jane Street, an estimated $6.2M sold.

Based on aggregated 13F filings for Q3 2019.